glp 1 drug market GLP-1 Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 Global GLP-1 Receptor Agonist Market
Description
The effects of this presentation on weight and glycemia in clinical trials and real-world settings are comparable to those induced by the subcutaneous presentation, although a specific indication for weight control without DT2 is still lacking.86 In order to avoid confusion in daily clinical practice, it is important to note that liraglutide 3mg and semaglutide 2.4mg can be used in patients with DT2, provided these are obese or overweight with comorbidities
NICE NG28 recommends considering an SGLT2 inhibitor as the preferred option in adults with type 2 diabetes and chronic kidney disease or heart failure, unless contraindicated or not tolerated
2025;329:G680-95
Catalents dozens of facilities cover small molecules, biologics, and cell therapy
Lundgren JR et al
At the same time, most telehealth players that have partnered with Novo or Lilly offer largely indistinguishable weight loss drug options
